(212)Pb: Production Approaches and Targeted Therapy Applications

Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived (212)Bi (T(1/2) = 1 h), provides the possibility for the synthesis and purification...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokov, Konstantin V., Egorova, Bayirta V., German, Marina N., Klabukov, Ilya D., Krasheninnikov, Michael E., Larkin-Kondrov, Antonius A., Makoveeva, Kseniya A., Ovchinnikov, Michael V., Sidorova, Maria V., Chuvilin, Dmitry Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777968/
https://www.ncbi.nlm.nih.gov/pubmed/35057083
http://dx.doi.org/10.3390/pharmaceutics14010189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777968/
https://www.ncbi.nlm.nih.gov/pubmed/35057083
http://dx.doi.org/10.3390/pharmaceutics14010189

Ejemplares similares